The AMC has developed a Barrett’s esophagus patient registry of 5,000 patients from 16 hospitals in the Amsterdam region. As a part of the collaboration, Cernostics will use the patient registry to complete clinical validation studies of its product TissueCypher: Barrett’s.
TissueCypher is designed to provide risk prediction for the development of esophageal cancer in Barrett’s esophagus patients.
More Articles on Gastroenterology:
4 Things to Know About Diet as IBS Therapy
14 Colonoscopy Quality Indicators to Consider
9 Things to Know About C. difficile Infection Diagnosis
